VOLABIOS
VOLABIOS Validation and Comparitive Multi-Omics Benchmarking of Fluid-Derived Volatilomics Biomarkers for the Prevention and Early detection of Schizophrenia VOLABIOS aims to transform the early detection and clinical management of schizophrenia (SZ) by leveraging innovative and real-time spectrograph technology to certify that volatile organic compounds (VOCs) can be utilized as non-invasive and cost-effective biomarkers for the early detection of the disease. Underscoring the urgent need for accurate, accessible diagnostic tools, VOLABIOS will conduct large-scale prospective clinical studies involving 3,692 participants across six European centres and a blind validation cohort of 1,000 subjects. Special emphasis is placed on the longitudinal monitoring of individuals at high risk to identify VOC signatures that indicate early transition to SZ. In order to gain further insights and to strengthen the evidence supporting the use of VOCs,…































































































